• Explore /
  • Poster
  • / MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status.

MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status.

Abstract Poster

Authors

null

Heinz-Josef Lenz

University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA

Heinz-Josef Lenz , Fa-Chyi Lee , Linda Yau , Han A. Koh , James A. Knost , Edith P. Mitchell , Ivan Bosanac , Christoph Mancao , Aparna Parikh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT01374425

Citation

J Clin Oncol 34, 2016 (suppl; abstr 3515)

DOI

10.1200/JCO.2016.34.15_suppl.3515

Abstract #

3515

Poster Bd #

212

Abstract Disclosures

Similar Posters

First Author: Heinz-Josef Lenz

First Author: Daniel H. Ahn

First Author: Zev A. Wainberg

First Author: Zev A. Wainberg